Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Association of Blood Pressure with Prostate Cancer Risk by Disease Severity and Prostate Cancer Death : A Pooled Cohort Study

Jochems, Sylvia H.J. LU ; Haggstrom, Christel ; Stattin, Par ; Jarvholm, Bengt and Stocks, Tanja LU (2022) In Cancer Epidemiology Biomarkers and Prevention 31(7). p.1483-1491
Abstract

Background: The association of blood pressure (BP) with prostate cancer risk after accounting for asymptomatic prostate-specific antigen (PSA) testing, and with prostate cancer death, is unclear. Methods: We investigated BP, measured at a mean age of 38 years among 430,472 men from five Swedish cohorts, in association with incident prostate cancer (n = 32,720) and prostate cancer death (n = 6718). HRs were calculated from multivariable Cox regression models. Results: Increasing systolic and diastolic BP levels combined were associated with a slightly lower prostate cancer risk, with a HR of 0.98 (95% CI, 0.97–0.99) per standard deviation (SD) of mid-BP (average of systolic and diastolic BP). The association was restricted to the PSA era... (More)

Background: The association of blood pressure (BP) with prostate cancer risk after accounting for asymptomatic prostate-specific antigen (PSA) testing, and with prostate cancer death, is unclear. Methods: We investigated BP, measured at a mean age of 38 years among 430,472 men from five Swedish cohorts, in association with incident prostate cancer (n = 32,720) and prostate cancer death (n = 6718). HRs were calculated from multivariable Cox regression models. Results: Increasing systolic and diastolic BP levels combined were associated with a slightly lower prostate cancer risk, with a HR of 0.98 (95% CI, 0.97–0.99) per standard deviation (SD) of mid-BP (average of systolic and diastolic BP). The association was restricted to the PSA era (1997 onwards, HR, 0.96; 95% CI, 0.95–0.98), to diagnoses initiated by a PSA test in asymptomatic men (HR, 0.95; 95% CI, 0.93–0.97), and to low-risk prostate cancer (HR, 0.95; 95% CI, 0.92–0.97). There was no clear association with more advanced disease at diagnosis. In cases, a slightly higher risk of prostate cancer death was observed for higher BP levels (HR, 1.05; 95% CI, 1.01–1.08) per SD of mid-BP; however, the association was restricted to distant metastatic disease (Pheterogeneity between case groups = 0.01), and there was no association for BP measured less than 10 years prior to diagnosis. Conclusions: Prediagnostic BP is unlikely an important risk factor for prostate cancer development and death. Less asymptomatic PSA testing among men with higher BP levels may explain their lower risk of prostate cancer. Impact: Elevated BP is unlikely to be an important risk factor for prostate cancer.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Cancer Epidemiology Biomarkers and Prevention
volume
31
issue
7
pages
9 pages
publisher
American Association for Cancer Research
external identifiers
  • scopus:85133980998
  • pmid:35511742
ISSN
1055-9965
DOI
10.1158/1055-9965.EPI-22-0159
language
English
LU publication?
yes
id
d2216d33-d78f-4ed7-a4a7-de3b0ee7e087
date added to LUP
2022-09-08 12:10:28
date last changed
2024-09-16 18:56:40
@article{d2216d33-d78f-4ed7-a4a7-de3b0ee7e087,
  abstract     = {{<p>Background: The association of blood pressure (BP) with prostate cancer risk after accounting for asymptomatic prostate-specific antigen (PSA) testing, and with prostate cancer death, is unclear. Methods: We investigated BP, measured at a mean age of 38 years among 430,472 men from five Swedish cohorts, in association with incident prostate cancer (n = 32,720) and prostate cancer death (n = 6718). HRs were calculated from multivariable Cox regression models. Results: Increasing systolic and diastolic BP levels combined were associated with a slightly lower prostate cancer risk, with a HR of 0.98 (95% CI, 0.97–0.99) per standard deviation (SD) of mid-BP (average of systolic and diastolic BP). The association was restricted to the PSA era (1997 onwards, HR, 0.96; 95% CI, 0.95–0.98), to diagnoses initiated by a PSA test in asymptomatic men (HR, 0.95; 95% CI, 0.93–0.97), and to low-risk prostate cancer (HR, 0.95; 95% CI, 0.92–0.97). There was no clear association with more advanced disease at diagnosis. In cases, a slightly higher risk of prostate cancer death was observed for higher BP levels (HR, 1.05; 95% CI, 1.01–1.08) per SD of mid-BP; however, the association was restricted to distant metastatic disease (P<sub>heterogeneity</sub> between case groups = 0.01), and there was no association for BP measured less than 10 years prior to diagnosis. Conclusions: Prediagnostic BP is unlikely an important risk factor for prostate cancer development and death. Less asymptomatic PSA testing among men with higher BP levels may explain their lower risk of prostate cancer. Impact: Elevated BP is unlikely to be an important risk factor for prostate cancer.</p>}},
  author       = {{Jochems, Sylvia H.J. and Haggstrom, Christel and Stattin, Par and Jarvholm, Bengt and Stocks, Tanja}},
  issn         = {{1055-9965}},
  language     = {{eng}},
  number       = {{7}},
  pages        = {{1483--1491}},
  publisher    = {{American Association for Cancer Research}},
  series       = {{Cancer Epidemiology Biomarkers and Prevention}},
  title        = {{Association of Blood Pressure with Prostate Cancer Risk by Disease Severity and Prostate Cancer Death : A Pooled Cohort Study}},
  url          = {{http://dx.doi.org/10.1158/1055-9965.EPI-22-0159}},
  doi          = {{10.1158/1055-9965.EPI-22-0159}},
  volume       = {{31}},
  year         = {{2022}},
}